Insmed

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insmed reports robust earnings, eyes pipeline expansion and regulatory support

Insmed's strong financial performance in 2022, driven by ARIKAYCE revenue and prudent cost management, sets a solid foundation for future growth. The company's focus on pipeline expansion, regulatory enthusiasm for brensocatib, and strategic milestones position it well for success. Challenges in the NTM market and pandemic-related impacts require careful navigation, but opportunities in new trials and gene therapy offer promising avenues for growth.

Insmed excels in Q1 with revenue growth and trial milestones

Insmed's strong Q1 performance driven by revenue growth and successful trial enrollments.
Challenges include regulatory differences and unblinding requirements for trial outcomes.
Opportunities lie in expanding ARIKAYCE's market reach and showcasing research efforts.
Financial stability and positive program reviews position Insmed well for future growth.

Insmed achieves record sales, strengthens capabilities in untreatable diseases

Insmed's Q2 2023 performance reflects robust sales growth, improved financial stability, and strategic acquisitions, positioning the company for future success.
The company's strengths lie in its commercial performance, innovative treatment formulations, and enhanced capabilities in synthetic rescue for untreatable diseases.
While facing challenges in clinical trial success and financial management, Insmed has opportunities to leverage its R&D portfolio, expedite drug approvals, and drive growth in key therapeutic areas.

Insmed reports record revenues and advances in trials, poised for growth

Insmed's Q3 2023 performance reflects record revenues for ARIKAYCE and positive trial results for brensocatib, positioning the company for continued growth.
Strong cash reserves, successful commercial activities, and promising trial data highlight Insmed's strengths and potential for future success in the biopharmaceutical market.
While facing funding challenges and trial complexities, Insmed has opportunities to leverage trial outcomes, enhance treatment efficacy, and secure financing for growth.
Overall, Insmed's strategic focus on product performance, financial stability, and innovation underscores its commitment to advancing therapies and driving shareholder value.

Insmed reports strong earnings, projects brensocatib sales exceeding $5B

Insmed's Q4 2023 earnings call highlighted strong financial performance, positive trial results, and strategic initiatives to maintain cash balance and drive commercial opportunities
The company's focus on patient-centric approaches, diverse early-stage assets, and opportunities for label expansion and commercial success position Insmed for future growth
While facing challenges related to placebo effects, regulatory requirements, and therapeutic advancements, Insmed's emphasis on reducing exacerbation rates and pursuing innovative therapies presents avenues for overcoming obstacles
With a robust cash position, promising pipeline developments, and a clear commercial outlook, Insmed demonstrates resilience and potential for market impact in the biopharmaceutical industry

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The mean of analysts' price targets for Insmed (INSM) points to a 98.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Insmed (INSM) Could Rally 98.26%: Here's is How to Trade

—Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses— —Treatment Discontinuation Rate of 15% Reported in Postmarketing ARISE Trial of ARIKAYCE® (amikacin liposome inhalation suspension) in Frontline Patients with MAC Lung Disease—Less than Half that of Pivotal Trial in Refractory Patients— —Blended, Blinded Event Rate Ranging from 1.12 to 1.15 Events Per Patient Per Year Reported in Phase 3 ASPEN Trial of Brensocatib in Patients with Bronchiectasis, in Line with Expectations— —Company Expects to Report 30% Global Revenue Growth for ARIKAYCE in 2022 Compared with 2021— —2023 Global ARIKAYCE Revenues Expected to be Between $285 Million and $300 Million— BRIDGEWATER, N.J. , Jan. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the Company's four pillars and outlined its near-term strategic priorities.

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J. , Jan. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 41st Annual J.P.

Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J. , Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 47th Investor Conference in London on Wednesday, December 7 at 8:30 a.m.

Insmed To Present at the Nasdaq 47th Investor Conference

BRIDGEWATER, N.J. , Nov. 1, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences: The Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, November 8, 2022, at 2:35 PM ET in a fireside chat The Stifel 2022 Healthcare Conference in New York, NY, on Tuesday, November 15, 2022, at 2:25 PM ET in a fireside chat The Evercore ISI 5th Annual HealthCONx Virtual Conference on Wednesday, November 30, 2022, at 8:50 AM ET in a fireside chat Each fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at  www.insmed.com.

Insmed To Present at Three November Conferences

--Insmed Leads Science Top Employers List for Second Year in a Row -- BRIDGEWATER, N.J. , Oct. 27, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has earned the highest ranking in Science's 2022 Top Employers Survey.

Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List

Insmed Incorporated (NASDAQ:INSM ) Q3 2022 Earnings Conference Call October 27, 2022 8:30 AM ET Company Participants Will Lewis - Chair & CEO Sara Bonstein - CFO Eleanor Barisser - IR Conference Call Participants Jeff Hung - Morgan Stanley Andrea Tan - Goldman Sachs Judah Frommer - Credit Suisse Joseph Schwartz - SVB Securities Liisa Bayko - Evercore ISI Jennifer Kim - Cantor Fitzgerald Operator Good morning, and afternoon, and evening. My name is Darius, and I will be your conference operator today.

Insmed Incorporated (INSM) Q3 2022 Earnings Call Transcript

Insmed (INSM) delivered earnings and revenue surprises of -22.47% and 0.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q3 Loss, Misses Revenue Estimates

—ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million, Marking the Strongest Quarter Since Launch — —Clinical Programs Progressing on Track; Company Expects to Complete Enrollment in Phase 3 ASPEN Trial of Brensocatib in First Quarter of 2023 and Share Topline Data in Second Quarter of 2024— —Recent Strategic Financings Increase Cash and Cash Equivalents and Marketable Securities to Approximately $1.3 Billion to Support Key Upcoming Milestones Across Four Pillars— BRIDGEWATER, N.J. , Oct. 27, 2022 /PRNewswire/ --  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update

The biotech company is raising money to help it launch another drug, but it's diluting current shareholders in the process.

Why Insmed's Shares Fell 14.7% on Wednesday

—$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing— —$275 million underwritten offering of common stock— —Financings increase cash and cash equivalents and marketable securities to approximately $1.3 billion— BRIDGEWATER, N.J. , Oct. 19, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced three strategic financings resulting in aggregate gross proceeds of $775 million.

Insmed Announces Strategic Financings Totaling $775 Million

BRIDGEWATER, N.J. , Oct. 13, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2022 financial results on Thursday, October 27, 2022.

Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022

— More than 500 Insmed employees volunteer across 13 sites in the U.S., Europe, and Japan — BRIDGEWATER, N.J. , Oct. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, holds its inaugural Global Day of Good today, with hundreds of Insmed employees volunteering simultaneously in their respective communities.

Insmed Holds Inaugural Global Day of Good - A Company-Wide Day of Service

Insmed (INSM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Insmed (INSM) Upgraded to Buy: What Does It Mean for the Stock?

BRIDGEWATER, N.J. , Sep. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor events: The Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY on September 12, 2022 at 9:55 a.m.

Insmed To Present at Two September Conferences

Insmed Incorporated (NASDAQ:INSM ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Eleanor Barisser - Investor Relations Will Lewis - Chair & Chief Executive Officer Sara Bonstein - Chief Financial Officer Conference Call Participants Jeff Hung - Morgan Stanley Andrea Tan - Goldman Sachs Judah Frommer - Credit Suisse Joori Park - SVB Securities Stephen Willey - Stifel Jennifer Kim - Cantor Fitzgerald Operator Good morning. My name is Dennis, and I will be your conference operator today.

Insmed Incorporated (INSM) CEO Will Lewis on Q2 2022 Results - Earnings Call Transcript

--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue of $65.2 Million, Marking the Strongest Quarter Since Launch -- --All Clinical Programs Progressing on Track-- --Company Reiterates Guidance of at Least 30% Revenue Growth in 2022 and Cash Runway into 2024 to Support Ongoing Programs-- BRIDGEWATER, N.J. , Aug. 4, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update

BRIDGEWATER, N.J. , July 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2022 financial results on Thursday, August 4, 2022.

Insmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022

BRIDGEWATER, N.J. , May 23, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022.

Insmed Names Drayton Wise Chief Commercial Officer

—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory Disease-Related Hospitalizations in the 12 Months Following ARIKAYCE® (amikacin liposome inhalation suspension) Initiation in Real-World Settings— —Post-Hoc Analysis of Phase 2 WILLOW Study in Adult Patients with Non-Cystic Fibrosis Bronchiectasis Supports Favorable Benefit-Risk Profile of Brensocatib— BRIDGEWATER, N.J. , May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from seven presentations across three of its pillars—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP)—at the American Thoracic Society (ATS) 2022 International Conference.

Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference

BRIDGEWATER, NJ,, May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference.

Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference

Insmed Inc. (NASDAQ:INSM ) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ET Company Participants Eleanor Barisser - IR Will Lewis - Chairman, CEO Sara Bonstein - CFO Conference Call Participants Andrea Tan - Goldman Sachs Anita Dushyanth - Berenberg Jeff Hung - Morgan Stanley Jennifer Kim - Cantor Fitzgerald Jessica Fye - JPMorgan Joseph Schwartz - SVB Securities Judah Frommer - Credit Suisse Ritu Baral - Cowen Stephen Willey - Stifel Operator Hello, everyone, and welcome to the Insmed First Quarter 2022 Financial Results Call. My name is Daisy, and I'll be coordinating today's call.

Insmed Inc. (INSM) CEO Will Lewis on Q1 2022 Results - Earnings Call Transcript

Insmed (INSM) delivered earnings and revenue surprises of 12.09% and 0.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million-- --Seven Clinical Trials Underway; Enrollment on Track in Brensocatib Phase 3 ASPEN Study and ARIKAYCE Post-Marketing Studies (ARISE and ENCORE)-- --Company Reiterates Revenue Guidance of at Least 30% Growth in 2022 and Cash Runway into 2024 to Support Ongoing Programs-- BRIDGEWATER, N.J. , May 5, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Insmed Reports First Quarter 2022 Financial Results and Provides Business Update

BRIDGEWATER, N.J. , April 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2022 financial results on Thursday, May 5, 2022.

News for Insmed Stock (INSM)